4//SEC Filing
Tak Paul Peter 4
Accession 0000950170-25-042725
CIK 0001841387other
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 4:35 PM ET
Size
7.0 KB
Accession
0000950170-25-042725
Insider Transaction Report
Form 4
Tak Paul Peter
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-03-19$9.00/sh−400$3,601→ 225,740 total - Sale
Common Stock
2025-03-18$8.77/sh−25,772$226,023→ 226,140 total
Footnotes (3)
- [F1]This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/19/2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.33 to $9.01, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 herein.
Documents
Issuer
Candel Therapeutics, Inc.
CIK 0001841387
Entity typeother
Related Parties
1- filerCIK 0001873905
Filing Metadata
- Form type
- 4
- Filed
- Mar 19, 8:00 PM ET
- Accepted
- Mar 20, 4:35 PM ET
- Size
- 7.0 KB